Circulating Tumor DNA May Help Identify Early Responses in CRC
Circulating tumor DNA can be an effective biomarker that allows for assessments of early response.
Caressa Valdueza Highlights Best Practices for the Management of Common Adverse Events in Melanoma
Caressa Valdueza, MSN, AGNP-BC, AOCNP, discusses toxicity management with unfolding treatment options in melanoma.
Real-World Study Demonstrates Benefits with Adjuvant Nivolumab in Resected Stage IIIA Melanoma
A significant portion of patients with resected stage IIIA melanoma were alive and recurrence free at a median follow-up of over 20 months following treatment with adjuvant nivolumab.
Pollack Discusses Ongoing Research for Patients With Refractory mCRC and Other Hard-to-Treat GI Malignancies
Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium
Nivolumab/Cabozantinib Shows Continued Benefit In Frontline Treatment of RCC
Goodman Highlights Potential Benefit of SBRT in Locally Advanced Pancreatic Cancer
